174 related articles for article (PubMed ID: 3111667)
21. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density.
Saggese G; Baroncelli GI; Bertelloni S; Perri G
J Pediatr; 1995 Sep; 127(3):395-402. PubMed ID: 7658269
[TBL] [Abstract][Full Text] [Related]
22. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
Aicardi G; Milani S; Imbimbo B; Vignolo M; Di Battista E; Gusmano R; Terragna A; Cordone G; Cottafava F; Coppo R
Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
[TBL] [Abstract][Full Text] [Related]
23. Immunosuppressive effects of deflazacort - a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: comparison with prednisone.
Hahn BH; Pletscher LS; Muniain M
J Rheumatol; 1981; 8(5):783-90. PubMed ID: 6458701
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid effects on statural growth.
Avioli LV
Br J Rheumatol; 1993 May; 32 Suppl 2():27-30. PubMed ID: 8495277
[TBL] [Abstract][Full Text] [Related]
25. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
[TBL] [Abstract][Full Text] [Related]
27. Growth retardation in juvenile chronic arthritis patients treated with steroids.
Falcini F; Taccetti G; Trapani S; Tafi L; Volpi M
Clin Exp Rheumatol; 1991; 9 Suppl 6():37-40. PubMed ID: 1711944
[TBL] [Abstract][Full Text] [Related]
28. Acute effects of deflazacort and prednisone on rates of mineralization and bone formation.
Lo Cascio V; Kanis JA; Beneton MN; Bertoldo F; Adami S; Poggi G; Zanolin ME
Calcif Tissue Int; 1995 Feb; 56(2):109-12. PubMed ID: 7736317
[TBL] [Abstract][Full Text] [Related]
29. Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.
Mayo AL; Craven BC; McAdam LC; Biggar WD
Neuromuscul Disord; 2012 Dec; 22(12):1040-5. PubMed ID: 22824639
[TBL] [Abstract][Full Text] [Related]
30. Deflazacort in giant cell arteritis.
Devogelaer JP; Gennari C
J Rheumatol; 2002 Oct; 29(10):2244-5. PubMed ID: 12375347
[No Abstract] [Full Text] [Related]
31. Preliminary experience with deflazacort, a new synthetic steroid with fewer undesirable side effects, in heart transplant patients.
Arizón JM; Anguita M; Vallés F; Montero A; Sancho M; López-Rubio F; Latre JM; Calleja F; Casares J; Román M
J Heart Lung Transplant; 1993; 12(3):445-8; discussion 448-9. PubMed ID: 8329416
[TBL] [Abstract][Full Text] [Related]
32. Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation.
Ferraris JR; Pennisi P; Pasqualini T; Jasper H
Pediatr Nephrol; 1997 Jun; 11(3):322-4. PubMed ID: 9203181
[TBL] [Abstract][Full Text] [Related]
33. Alterations in calcium, vitamin D, and parathyroid hormone physiology in normal men with aging: relationship to the development of senile osteopenia.
Orwoll ES; Meier DE
J Clin Endocrinol Metab; 1986 Dec; 63(6):1262-9. PubMed ID: 3023418
[TBL] [Abstract][Full Text] [Related]
34. Bone mineral content and bone mineral metabolism: changes after growth hormone treatment in juvenile chronic arthritis.
Rooney M; Davies UM; Reeve J; Preece M; Ansell BM; Woo PM
J Rheumatol; 2000 Apr; 27(4):1073-81. PubMed ID: 10782840
[TBL] [Abstract][Full Text] [Related]
35. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
36. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis.
Rebollo Bernárdez J; Cifuentes Mimoso C; Piñar Moreno A; Caunedo Alvarez A; Salas Herrero E; Jiménez-Sáenz M; Herrerías Gutiérrez J
Rev Esp Enferm Dig; 1999 Sep; 91(9):630-8. PubMed ID: 10502711
[TBL] [Abstract][Full Text] [Related]
37. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
[TBL] [Abstract][Full Text] [Related]
38. Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids.
Reeve J; Loftus J; Hesp R; Ansell BM; Wright DJ; Woo PM
J Rheumatol; 1993 Jul; 20(7):1189-95. PubMed ID: 8371216
[TBL] [Abstract][Full Text] [Related]
39. Deflazacort vs prednisone. Effect on blood glucose control in insulin-treated diabetics.
Bruno A; Cavallo-Perin P; Cassader M; Pagano G
Arch Intern Med; 1987 Apr; 147(4):679-80. PubMed ID: 3827456
[TBL] [Abstract][Full Text] [Related]
40. Mineral metabolism in obese children.
Zamboni G; Soffiati M; Giavarina D; Tató L
Acta Paediatr Scand; 1988 Sep; 77(5):741-6. PubMed ID: 2849283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
